Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) | PAR 21 056

Frequently Asked Questions (FAQs) - NIH PAR 21-056 (U01) Biomarker Analytical Validation

1) What is PAR 21-056 funding?

PAR 21-056 is a National Institutes of Health (NIH) cooperative agreement funding opportunity using the U01 mechanism (clinical trial optional). It supports analytical validation of a single, well-supported candidate biomarker for neurological or neuromuscular diseases and conditions.

2) What is the main purpose of this opportunity?

The goal is to rigorously validate the measurement method (assay) for one promising biomarker so the assay performs consistently and reliably under defined conditions. The program is intended to move an assay from a lab-specific proof of promise to a reproducible method with clearly documented performance characteristics that others can trust across settings.

3) Is this program meant for discovering new biomarkers?

No. The core intent is not biomarker discovery. The emphasis is on analytical validation of an already identified biomarker that has strong supporting rationale and evidence.

4) How many biomarkers can be proposed in one application?

The opportunity is focused on analytical validation of a single candidate biomarker.

5) What must already exist before applying?

The announcement assumes three prerequisites are already in place: (1) the biomarker has been identified and is well-supported, (2) a detection technology or assay method has already been developed (the work is not primarily inventing a brand-new platform), and (3) there is a defined research and/or clinical need plus a plausible context of use for how the biomarker measurement is intended to be used.

6) What does "context of use" mean here?

It means applicants should explain how the biomarker measurement is intended to be used in a realistic setting. Examples described include use as a pharmacodynamic marker, a disease progression indicator, a patient selection tool, or another clearly described use case. Full clinical validation is not the primary focus at this stage, but the intended use should be plausible and well-articulated.

7) What kinds of activities are considered "analytical validation" for this program?

The technical emphasis is on characterizing the assay and establishing performance characteristics in a rigorous, FDA-aligned manner. The description signals typical analytical validation expectations such as assessing precision and reproducibility, accuracy or trueness where reference materials exist, analytical sensitivity (including limits of detection/quantification), analytical specificity and interference testing, linearity and dynamic range, sample/reagent stability, robustness to small procedural variations, and clearly defined quality control and acceptance criteria.

8) Does the opportunity specify exact validation parameters that must be tested?

The excerpt does not list every required parameter explicitly. However, it states the validation should be consistent with FDA guidelines, which signals the types of performance characteristics typically expected in analytical validation work.

9) What would a strong validation plan generally include, based on the announcement?

Based on the described expectations, a strong application would translate FDA-aligned analytical validation concepts into a concrete plan with standardized operating procedures, pre-specified performance targets, defined operating conditions, and a clear strategy for documenting and reporting results so others can replicate the method.

10) Does this funding opportunity require a clinical trial?

No. It is designated "clinical trial optional," meaning a clinical trial is not required.

11) Can applicants include clinical study elements anyway?

Yes. Clinical components may be included if they are needed to support the analytical validation objectives (for example, using clinical specimens to test assay performance across relevant patient populations), as long as the work fits NIH definitions and requirements.

12) What does it mean that this is a cooperative agreement (U01)?

A U01 is a cooperative agreement, which typically involves substantial NIH programmatic involvement compared with a standard research grant. Awardees should generally expect active coordination with NIH staff on items such as milestones, progress oversight, and data/method standardization.

13) Who is eligible to apply?

Eligibility is broad across U.S.-based organizations. The excerpt lists eligible applicants including (among others): state/county/local governments; special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; Native American tribal governments (federally recognized); tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.

14) Are specific institution types called out as eligible?

Yes. The announcement highlights additional eligible types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and Indian/Native American Tribal Governments other than federally recognized entities.

15) Can non-U.S. (foreign) organizations apply?

No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply under this opportunity.

16) Can a U.S. organization apply if part of the work will be done outside the United States?

The excerpt states that non-domestic components of U.S. organizations are not eligible to apply, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. In practical terms, the application must be fully domestic in organizational scope and performance sites, consistent with the stated restrictions.

17) What diseases or conditions are in scope?

The opportunity targets biomarkers for neurological or neuromuscular diseases and conditions.

18) What agency administers the opportunity?

The funding opportunity is run by the National Institutes of Health (NIH).

19) What is the CFDA number and category for this opportunity?

The excerpt describes it as a discretionary funding opportunity in the health category under CFDA number 93.853.

20) When was the opportunity created and what closing date is listed?

The opportunity was created on 2020-11-19, and the original closing date listed in the excerpt is 2023-09-07.

21) Does the excerpt provide the award ceiling or expected number of awards?

No. The posted excerpt does not provide an award ceiling or the expected number of awards. Applicants would typically need to consult the full NIH notice or related institute-specific guidance for budget expectations, project period norms, and any institute priorities.

22) What types of teams are the best fit for this program?

The best fit is a team that already has a compelling biomarker and an existing assay approach, and now needs structured, FDA-consistent analytical validation work to define reliability, operating conditions, and documented performance so the measurement method can be trusted for downstream clinical research and potential future regulatory discussions.

23) What is the expected end result of a successful project (as described)?

A key expected outcome is an analytically validated biomarker measurement method with clearly documented performance characteristics, optimized conditions for accuracy and reproducibility, and reporting/documentation that supports use across settings.

24) Is the program focused on clinical validation of the biomarker?

The emphasis described is analytical validation of the measurement method. While a context of use should be articulated, full clinical validation is not presented as the primary focus at this stage.

25) How does FDA alignment show up in what NIH expects for this work?

The excerpt indicates the analytical validation should be consistent with FDA guidelines, which implies rigorous, pre-specified evaluation of assay performance (for example precision/reproducibility, sensitivity, specificity/interference, linearity/range, stability, robustness, and clear QC/acceptance criteria) and thorough documentation so results are reproducible and dependable.